Posts by Matthew J. Frigault, MD
-
Neutropenia-driven Approach to G-CSF Use May Be Feasible With CAR T-Cell Therapy
Mass General Cancer Center researchers found using granulocyte colony-stimulating factor to treat neutropenia after chimeric antigen receptor T-cell therapy, rather than as prophylaxis, resulted in less risk of severe cytokine release syndrome (CRS). Initiating G-CSF after CRS onset did not exacerbate toxicity.
-
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy
Massachusetts General Hospital researchers observed low rates of acute kidney injury (AKI) after tisagenlecleucel therapy but detected the first case of AKI in a patient with macrophage activation syndrome/hemophagocytic lymphohistiocytosis triggered by the therapy.
-
CAR T-cell Therapy Feasible for Active Secondary CNS Lymphoma
Central nervous system involvement does not appear to be a risk factor for severe neurotoxicity with CD19-directed CAR T-cell therapy.
-
Cardiac Injury and Cardiovascular Events Are Common After CAR T Therapy
Mass General researchers have reported the first registry data on cardiac toxicities and cardiovascular events among adult patients who received chimeric antigen receptor T-cell therapy.
